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Background: Respiratory tract infections (RTIs) remain among of the most important causes of morbidity and
mortality among children. Several studies have associated vitamin D deficiency with an increased risk of RTIs, and
vitamin D supplementation has been proposed as a possible preventive measure against RTIs in children. The main
aim of this review is to summarize the current evidence from the literature about the link between vitamin D and
RTIs in children.
Discussion: Several recent studies have shown that vitamin D has different immunomodulatory properties
associated with the risk of RTIs in childhood. In this regard, it is very important to understand the definition of
deficiency and insufficiency of vitamin D and when and how to treat this condition. Unfortunately, there is no
consensus, although a level of at least 10 ng/mL 25-hydroxycholecalciferol (25[OH]D) is thought to be necessary to
promote bone mineralization and calcium homeostasis, and a concentration between 20 ng/mL and 50 ng/mL is
considered adequate to provide an immunomodulatory effect. Available data support a role for vitamin D
deficiency in the risk of pediatric tuberculosis, recurrent acute otitis media, and severe bronchiolitis, whereas further
studies are needed to confirm an association in children with recurrent pharyngotonsillitis, acute rhinosinusitis and
community-acquired pneumonia.
Conclusions: Maintenance of adequate vitamin D status may be an effective and inexpensive prophylactic method
against some RTIs, but the supplementation regimen has not been clearly defined. Further clinical trials are needed
to determine the 25(OH)D concentrations associated with an increased risk of RTIs and optimal vitamin D
supplementation regimen according to the type of RTI while also taking into consideration vitamin D receptor
polymorphisms.
Keywords: Acute otitis media, Bronchiolitis, Community-acquired pneumonia, Pharyngotonsillitis, Respiratory tract
infection, Rhinosinusitis, Vitamin D, Vitamin D supplementationBackground
Vitamin D, or the “sunshine vitamin,” is not just a
vitamin; it is also a prohormone with numerous func-
tions in the body [1]. “Prohormone” refers to a group of
fat-soluble secosteroids. The two major forms are vita-
min D2, or ergocalciferol, and vitamin D3, or cholecal-
ciferol [2]. The best-understood function of vitamin D is
in the absorption of calcium from the small intestine,
which helps to prevent diseases such as osteoporosis and
osteomalacia in adults and rickets in children [3–7]. In
addition to its important role in skeletal development* Correspondence: susanna.esposito@unimi.it
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vitamin D has a beneficial effect on extraskeletal tissues.
Tissues such as the brain, heart, stomach, pancreas, lym-
phatics, skin, gonads, and prostrate tissue are composed
of cells, including T and B lymphocytes, that express the
vitamin D receptor (VDR). In these tissues, vitamin D is
thought to have roles in the improvement of immune
function and the reduction of inflammation [8, 9]. Ac-
cordingly, there is accumulating evidence that consump-
tion of vitamin D may reduce respiratory tract infection
(RTI) susceptibility in children [10, 11]. Initially, the
prototypical disease link was tuberculosis (TB), but there
are now studies that support a connection with several
others RTIs, such as acute otitis media (AOM), pharyn-
gotonsillitis, rhinosinusitis, bronchiolitis and pneumoniaarticle is distributed under the terms of the Creative Commons Attribution 4.0
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evidence in the literature of the link between vitamin D
and RTIs in children.
Discussion
Vitamin D metabolism
Vitamin D2 (ergocalciferol) and vitamin D3 (cholecal-
ciferol) can be ingested from different types of food
(Table 1), or they can be synthesized through exposure
to ultraviolet radiation B (UVB) [14]. Skin synthesis usu-
ally contributes 80 to 90 % of an individual’s vitamin D,
but it depends on several factors. For example, people
with darker skin have higher levels of the pigment mel-
anin, which reduces the skin’s ability to produce vitamin
D after sun exposure [15]. People at risk for vitamin D
deficiency include those with limited sun exposure and
those with fat malabsorption [16]. Subjects living in the
northern latitudes, homebound individuals, and women
who wear long robes and head coverings for religious
reasons may also not obtain adequate levels of vitamin
D from sunlight [16]. Finally, after the age of fifty, the skin
loses its ability to efficiently synthesize vitamin D and the
kidneys also convert less to its active form [17–20].
Both the ingested and UVB-synthesized forms of
vitamin D are biologically inactive; activation requires
hydroxylation in the liver and kidney. In the liver,
cholecalciferol is converted to calcidiol (also known
as 25-hydroxycholecalciferol, 25[OH]D), whereas ergo-
calciferol is converted to 25-hydroxyergocalciferol [21].
Part of the calcidiol is converted by the kidneys to
calcitriol (1,25-dihydroxyvitamin D3, 1,25[OH]D), the
biologically active form of vitamin D; the conversion is
controlled by the parathyroid glands [22]. Calcitriol circu-
lates as a hormone in the blood, regulating several mecha-
nisms, and its level depends on the number of nephrons,
high serum concentrations of fibroblast growth factor-23,
and the level of inflammatory cytokines [23]. Calcitriol is
also produced in tissues such as vascular smooth muscle
cells, bowel cells, monocytes, dendritic cells (DCs), and B
lymphocytes [24–30].
VDRs and polymorphisms
The effects of vitamin D are mediated by a cytosolic re-
ceptor called VDR. VDR is nearly ubiquitously expressed,Table 1 The principal foods containing vitamin D
Main food sources of vitamin D
Fatty fish (e.g., tuna, salmon, mackerel)
Liver
Cheese
Milk (fortified)
Egg
Other fortified foods (e.g., cereals)and this ubiquity accounts for the numerous and varied
mechanisms that are regulated by vitamin D [31]. After its
production, 1,25(OH)D binds VDR and then enters the
cell nucleus, acting as a ligand-activated transcription
factor and activating gene expression [32, 33]. The VDR
gene, which is located on chromosome 12q13.1, has sev-
eral polymorphic regions, some of which are associated
with a predisposition for certain diseases [34]. This means
that not only is vitamin D deficiency is associated with a
considerable risk of diseases, but there is wide interindi-
vidual variation in vitamin D sensitivity, which may
influence disease risk. Until now, only a few polymor-
phisms have been studied, and a complete understanding
of these complex mechanisms has been lacking [35].
This means that future studies should focus on the
functional effects of genetic variations in VDRs and
their association with RTIs among pediatric patients
with different characteristics.
Vitamin D as an immune system regulator
Vitamin D has an important influence on the host’s
immune system, modulating both innate and adaptive im-
munity and regulating the inflammatory cascade [36–38].
The hypothesis of the immunoregulatory role of vitamin
D derives from the discovery that there are several interac-
tions between vitamin D and the immune system. The
majority of immune cells express VDRs, mainly after they
themselves have been stimulated [39]. The mechanism by
which vitamin D regulates inflammation and immunity
appears to be pleiotropic; it controls macrophage and
dendritic cell activities and various Toll-like receptor-
mediated events in neutrophils [39], and it diminishes the
function of human dendritic cells by decreasing ma-
turation, antigen presentation and the production of
cytokines such as interleukin (IL)-12 and IL-23 [40].
Moreover, treating macrophages with 1,25(OH)D results
in the expression of various cytokines and chemokines,
including CXCL8, IL-6, and IL-12, and tumor necrosis
factor (TNF)-α [41, 42]. Additionally, vitamin D induces
the expression of two antimicrobial peptides—cathelicidin
and β-defensin—that are widely expressed in the body and
play a key role in innate immunity owing to their chemo-
tactic action and toxin neutralization [37, 38]. Vitamin D
shifts cytokine expression from a type-1 to a type-2
phenotype: it represses the transcription of genes encod-
ing type-1 cytokines (connected with Th1-driven auto-
immune responses) and Th17-associated cytokines (linked
to tissue damage and inflammation) in order to polarize
CD4+ T-cells responses toward more regulatory type-2 or
Treg phenotypes [43–45]. Thus, 1,25(OH)D seems to
contribute to the maintenance of self-tolerance by enhan-
cing protective innate responses. Finally, more evidence of
a connection between inflammation and vitamin D comes
from a recent study that demonstrated that VDR
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with degrees of ongoing inflammation, possibly resulting
from alterations in gut permeability and microbial trans-
location [46].
With this background, several studies have evaluated
whether vitamin D deficiency is associated with an
increased risk of RTIs in children [12, 13, 47, 48].
Vitamin D and respiratory infections in children
In children, infections are a major cause of morbidity
and mortality [49, 50]. Numerous studies have identified
an association between inadequate vitamin D concentra-
tions and RTIs in children [51]. Initially, an association
between vitamin D deficiency and RTIs in children was
found after a higher incidence of respiratory infections
was found among infants and children with rickets [51].
The increased incidence of RTIs in these children was
probably caused by both compromised lung compliance
due to the rib deformities associated with severe rickets
and poor nutritional status.
Later, the prototypical example of a connection be-
tween vitamin D insufficiency and susceptibility to infec-
tious disease was found to be TB; studies published over
the past twenty years have noted the link between
decreased serum calcitriol concentrations and increased
severity and/or susceptibility to TB infection [52, 53].
Gradually, other RTIs in children have also been
linked to vitamin D. The evidence that the peak of viral
infections is in the winter months when synthesis of
vitamin D across the skin is naturally impaired sup-
ported the association [54]. In addition, vitamin D defi-
ciency in pregnant women may result in an increased
risk of RTIs in their infants. It has been shown that
serum 25(OH)D levels during pregnancy can condition
the expression of certain tolerogenic genes connected
with diseases other than congenital rickets [55]. Thus,
vitamin D supplementation during pregnancy appears to
have a beneficial effect on children’s health.
Vitamin D and TB
In 2000, a case–control study of the Gujarati Indian
population in London found that serum vitamin D defi-
ciency was more common in patients with active TB
(67 %) than in their uninfected co-inhabitants (26 %;
odds ratio [OR] 0.68, with a 95 % confidence interval
[CI] 0.43-0.93) who served as the control group [53].
The seasonality of TB observed in several countries in
Europe and South Africa [56–58] was considered to be
proof of this link. The mechanisms through which vita-
min D modulates the immune system in response to
Mycobacterium tuberculosis infection are not completely
understood. Some studies have demonstrated that cal-
citriol induces anti-mycobacterial activity in vitro by
modulating the host response to mycobacterial infection[59–64]. These studies have shown that vitamin D in-
duces reactive nitrogen and oxygen, which inactive
matrix metalloproteinase enzymes (MMPs) implicated in
the pathogenesis of pulmonary cavitation, with calcitriol
decreasing tissue damage by inhibiting MMPs [59–64].
Vitamin D also induces the antimicrobial peptide cathe-
licidin, which stimulates autophagy of M. tuberculosis
[59–64]. However, there are interindividual differences
that are determined by VDR polymorphisms. The TaqI
VDR polymorphism has been associated with an in-
creased phagocytosis of M. tuberculosis by vitamin D
in vitro and a more rapid sputum culture conversion in
patients with pulmonary TB [65, 66]. By contrast, the
FokI VDR polymorphism reduced this antimicrobial
activity [66, 67].
More than 20 years ago, Davies et al. proposed that
vitamin D would be more effective as a treatment for la-
tent TB infection rather than for active disease [67, 68].
However, a recent multicenter randomized controlled
trial in which 146 patients were allocated to receive
2.5 mg vitamin D or placebo at baseline and 14, 28, and
42 days after starting standard TB treatment demon-
strated that vitamin D did not significantly affect time to
sputum culture conversion in the entire study popula-
tion but significantly hastened sputum culture conver-
sion in participants with the TT genotype of the TaqI
VDR polymorphism [69]. Moreover, low serum levels of
1,25(OH)D were associated with a higher risk of devel-
oping multidrug-resistant TB (MDR TB) [70]. Some
recent clinical observational studies have shown that
vitamin D levels are significantly lower in children with
latent TB and active TB than in children without TB
[52, 71, 72]. Recently, the correlation between low
vitamin D and TB disease was confirmed in a multi-
center observational study that included 996 children
screened for TB [73]. Vitamin D was considered defi-
cient if the serum 25(OH)D level was <25 nmol/L, insuf-
ficient between 25 and 50 nmol/L and sufficient at a
level >50 nmol/L. Vitamin D levels were significantly lower
in children with latent TB than in controls (p = 0.002), in
children with active TB than in controls (p < 0.0001), and
in children with active TB than in those with latent
TB (p = 0.001). Moreover, deficient vitamin D levels
were found in a higher percentage in the active TB
group (n = 18; 40.9 %) compared with the latent TB
group (n = 28; 20.3 %) and controls (13.9 %) (p < 0.0001),
confirming that hypovitaminosis D was significantly
associated with TB infection [73]. Finally, a study of 266
Indian children with intrathoracic TB showed that 186
(69.9 %) children were vitamin D deficient (serum
25[OH]D <12 ng/mL), 55 (20.7 %) were insufficient
(12 to <20 ng/mL) and 25 (9.4 %) were vitamin D
sufficient (≥20 ng/mL) [74]. Levels of 25(OH)D were
similar in all three types of intrathoracic TB, and in
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25(OH)D did not significantly affect outcome of the dis-
ease. Children who were deficient or insufficient were less
likely to convert (i.e., become smear/culture negative) after
an intensive phase of antituberculous therapy at two
months as compared to those who were 25(OH)D suffi-
cient (p < 0.05) [74].
A research on the value of administering vitamin D to
children with TB was carried by Marcos et al.; in a
randomized study performed in a small number of
children (n = 24), vitamin D supplementation (cholecalcif-
erol 1000 IU daily for 8 weeks) was added to TB treatment,
leading to better clinical and radiological outcomes
compared with the standard treatment alone [75].
Overall, these data showed that low vitamin D is
associated with latent TB and active TB. Given the TB
burden worldwide and the increase in MDR TB cases, it
is very important to find new mechanisms that might
reduce the risk of disease and enhance standard treat-
ment efficacy. This highlights the need for further
studies to confirm the possible role of vitamin D in the
prevention of TB as well as in supportive treatment.
Vitamin D and AOM
AOM is a very common problem in pediatric popula-
tions, affecting approximately 50 % of infants worldwide
in the first year of life. [76, 77]. A subset of children with
AOM present with recurrent AOM (rAOM), which is
defined as three or more AOM episodes in six months
or four or more AOM episodes within 12 months [78].
rAOM is associated with high direct and indirect costs,
including antibiotic use and lost working days for par-
ents [78]. Consequently, preventive methods, including
prolonged breastfeeding, avoidance of tobacco smoke,
nonuse of a pacifier, pneumococcal and influenza vaccin-
ation, and supplementation with vitamin D, are ex-
tremely important and appear to be effective [79–81].
The first study to suggest an association between vita-
min D and AOM was conducted by Sun et al. in rats
with rickets [82]. In a subsequent study’s cohort of 475
school-aged children from Bogota, vitamin D deficiency
was associated with increased rates of diarrhea with
vomiting and earache with fever [83]. More recently,
Cayir et al., in a randomized, single-blind, case–control
study, concluded that serum calcitriol levels were signifi-
cantly lower in children diagnosed with AOM than in
controls without AOM, suggesting that vitamin D defi-
ciency plays a role in AOM risk [84]. Finally, our group
prospectively and blindly randomized 116 children with
a history of rAOM to receive oral vitamin D supplemen-
tation of 1000 IU/day or placebo for 4 months [85]. The
results showed that the number of children with at least
one AOM episode during the study period was signifi-
cantly lower in the treatment group than in the groupthat received the placebo. Administration of 1000 IU/day of
vitamin D restored serum 25(OH)D values of ≥30 ng/mL
in most cases and was associated with a significant reduc-
tion in the risk of uncomplicated AOM with no benefit
for spontaneous otorrhea [85]. Similarly, Cayir et al. dem-
onstrated in a prospective study that serum 25(OH)D
levels in patients with rAOM were lower than those in
children without rAOM, and a significant reduction in
disease frequency was recorded following vitamin D sup-
plementation [86].
In addition, for AOM the overall results suggested that
low 25(OH)D serum values are associated with an in-
creased risk of disease. Considering the high frequency
of AOM in the pediatric population, studies are needed
to identify the serum levels associated with an increased
risk of disease and to determine whether vitamin D sup-
plementation can prevent overall AOM cases in children
or reduce recurrent episodes in those who already have
a history of rAOM.
Vitamin D and acute pharyngotonsillitis
Acute pharyngotonsillitis is one of the leading causes of
hospital visits during childhood [87, 88]. Most cases are
of viral etiology, and among bacterial cases the most
important are those caused by Streptococcus pyogenes
because of their possible complications [89]. Some
children have recurrent episodes of pharyngotonsillitis.
Recurrent pharyngotonsillitis is defined as at least 7 epi-
sodes of pharyngotonsillitis in a year or at least 5 epi-
sodes in a year for two consecutive years or at least 3
episodes in a year for three consecutive years [90]. Re-
current pharyngotonsillitis seems to be associated with
the bacterial biofilm formation on tonsillar tissue, and
antibiotics have low efficacy against them [91]. Prevent-
ive therapies are useful in these recurrent cases to avoid
tonsillectomy [90].
Vitamin D may have a preventive role in recurrent
pharyngotonsillitis by inhibiting the formation of bac-
terial biofilms, but there are few published studied on
this topic. Reid et al. enrolled 33 children in New
Zealand who were undergoing tonsillectomy for difficult
breathing/sleep apnea and/or recurrent pharyngotonsilli-
tis [92]. They measured 25(OH) vitamin D, iron and zinc
levels. Of the 33 patients, 78 % had a 25(OH) vitamin D
level <75 nmol/L, and 15.6 % had levels <50 nmol/L.
Low 25(OH) vitamin D levels have been linked to risk
factors such as darker skin and increased body mass
index (BMI) [93]. Yildiz et al. showed that a low serum
vitamin D level may be a risk factor for recurrent phar-
yngotonsillitis because children who had recurrent
episodes had serum 25(OH) vitamin levels that were
lower than those in healthy children [94]. Since 2012,
only one other study has been published on the relation-
ship between serum vitamin D levels and recurrent
Esposito and Lelii BMC Infectious Diseases  (2015) 15:487 Page 5 of 10pharyngotonsillitis, and it was performed in adults. It
showed a link between vitamin D deficiency and recur-
rence of streptococcal pharyngotonsillitis [95].
Although vitamin D supplementation may have a role
in the inhibition of biofilm formation, the data are insuf-
ficient to allow definitive conclusions to be drawn about
the efficacy of this type of supplementation. Further
studies would be useful.
Vitamin D and rhinosinusitis
Rhinosinusitis (RS) is also extremely common in chil-
dren, with 0.5–5 % of upper respiratory tract infections
progressing to this condition [96]. A few years ago, a
retrospective study evaluated serum 25(OH)D levels in
children with allergic RS with or without nasal polyposis
and found no difference in mean vitamin D3 levels be-
tween controls and RS without polyposis, whereas the
levels in children with allergic RS with polyposis were
lower than the recommended levels [97]. Mullingan
et al. confirmed these results in a study performed in
adults [98]. In this study, the authors also wanted to de-
termine the effect of cigarette smoke on vitamin D3
levels, conversion, and the regulation of inflammation.
All the patients exposed to smoke had lower vitamin D3
levels, and the authors suggested that the reduction of
vitamin D3 by cigarette smoke exposure is a novel
mechanism through which cigarette smoke induces
proinflammatory effects [98].
Because further evidence supports an association of low
25(OH)D with chronic rhinosinusitis in adults [99, 100],
and considering that pediatric rhinosinusitis is mainly
acute and characterized by the absence of polyposis,
studies performed in the pediatric population are urgently
needed to clarify the role of vitamin D in children with
single or recurrent episodes of acute rhinosinusitis.
Vitamin D and acute lower respiratory tract infections:
bronchiolitis and pneumonia
Acute lower respiratory tract infection (ALRI) is an im-
portant cause of global child mortality, annually account-
ing for approximately 1.4 million deaths of children
younger than 5 years of age [49]. As early as 1975,
Salimpour hypothesized a link between vitamin D and
pneumonia. Studying 200 rachitic children in Tehran, he
found that 43 % also had a history of ALRI [101]. Subse-
quently, Najada et al. studied a cohort of hospitalized
infants with respiratory diseases and found a higher inci-
dence of nutritional rickets [51]. Wayse et al. studied
ALRIs in children without rickets admitted to a private
hospital in India and recognized a link between sub-
clinical vitamin D deficiency, non-exclusive breastfeeding,
and increased risk for severe ALRIs [102]. In addition, a
meta-analysis of randomized controlled trials showed that
prophylactic vitamin D supplementation in pediatricsubjects significantly reduced the odds of contracting RTIs
(OR, 0.58; 95 % CI, 0.41–0.8) [103]. Interestingly, low cord
blood 25(OH)D levels in neonates admitted to neonatal
intensive care units have been associated with an in-
creased risk of lower RTIs in the first 2 years of life [104].
To avoid neonatal deficiency and enhance newborns’ re-
spiratory health, it has been proposed that vitamin D sup-
plementation be administered during pregnancy and early
childhood [105]. Karatekin et al. found that in 87.5 % of
all newborns admitted to neonatal intensive care units,
and in 67.5 % of all mothers, serum 25(OH)D concentra-
tions were lower than 20 ng/mL [106]. The 25(OH)D con-
centrations of newborns were highly correlated with
mothers’ serum 25(OH)D concentrations, and for this rea-
son vitamin D supplementation during pregnancy seems
beneficial for the neonate.
Bronchiolitis is a viral infectious disease caused mainly
by respiratory syncytial virus (RSV) [107]. Some evi-
dence suggests that vitamin D may protect against se-
vere RSV bronchiolitis because in vitro it has been
shown that vitamin D decreases the inflammatory re-
sponse of airway epithelial cells to RSV infection [108].
Moreover, genetic polymorphisms in VDR have been as-
sociated with hospitalization for acute bronchiolitis in
infancy [109]. A meta-analysis of the existing literature
on VDR polymorphisms supported an association be-
tween the Fokl VDR and RSV severity [110]. In addition,
several studies have demonstrated that serum 25(OH)D
levels are lower in infants hospitalized for acute
bronchiolitis than in with healthy controls [111, 112].
Randolph et al. reported an association between a vita-
min D binding protein haplotype and hospitalization for
RSV bronchiolitis in infancy in two independent cohorts
[113]. By contrast, a Canadian study found no cor-
relation between lower vitamin D levels and risk of
hospitalization for ALRI when 25(OH)D concentrations
were measured in children hospitalized with bronchio-
litis [114].
Some authors hypothesized that vitamin D supplemen-
tation in mothers during pregnancy would be useful to
prevent acute respiratory infection including bronchio-
litis. Belderbos et al. demonstrated that neonates born
with a serum 25(OH)D concentration of approximately
50 nmol/L had an important (95 % CI: 1.6-24.9; p = 0.01)
increase in risk of acute lower RTI due to RSV in the
first year of life compared with those who had 25(OH)D
concentrations of approximately 75 nmol/L. [115]. In
addition, Camargo et al. demonstrated that a higher
maternal intake of vitamin D during pregnancy may
decrease the risk of recurrent wheeze in early childhood
[116]. Overall, these data suggest that vitamin D supple-
mentation for pregnant women and infants may be a
useful strategy for preventing and reducing severity of
viral respiratory infections that cause bronchiolitis.
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and its morbidity and mortality in children, several inter-
ventions have been evaluated to prevent it, including
supplementation with vitamin D [117]. Muhe et al. per-
formed a case–control study to determine the role of
nutritional rickets in the development of pneumonia,
analyzing 521 Ethiopian children with nutritional rickets
[118]. Rickets was present in 210 of 500 cases compared
with 20 of 500 controls (OR, 22.11; 95 % CI, 11.34–
43.12; p < 0.0001.). After correction for confounding fac-
tors such as family size, birth order, crowding, and
months of exclusive breastfeed by logistic regression, the
authors concluded that vitamin D or calcium deficiency
may be important predisposing factors for pneumonia in
children under 5 years of age in developing countries.
Later, a case–control study involving 24 Nigerian chil-
dren showed that not only vitamin D insufficiency but
also vitamin D deficiency may have an important role in
immune system control [119]. Similar results were found
by Haider et al. in 137 Pakistan children [120]. More re-
cently, in 103 children with CAP, Ren et al. found that
the mean vitamin D concentration in the group with se-
vere CAP was significantly lower than that in the mild-
CAP and control groups (p < 0.01), and there was no sig-
nificant difference between the mild-CAP and control
groups (p = 0.674) [121]. Zhou et al. measured the serum
level of some vitamins and trace elements in a cohort of
children with CAP who were randomized into interven-
tion and non-intervention groups with vitamin D sup-
plementation; healthy children of the same age served as
controls [122]. Vitamin D serum levels in the CAP
group were lower than in children who had CAP and a
history of asthma than in the non-asthmatic CAP group
or the control group. After vitamin D supplementation,
vitamin D serum levels in the asthmatic CAP group
increased significantly [122]. VDR polymorphisms seem
to be important in relation to CAP risk. A study among
children in a Chinese Han population demonstrated that
the TT genotype of rs2239185 in the VDR gene may be
a genetic risk factor for CAP, and the T allele of
rs2239185 may be associated with CAP susceptibility
and severity [123].
Studies have been conducted to investigate whether
vitamin D supplementation could be useful during the
treatment of CAP to improve outcomes. Manaseki-
Holland et al. demonstrated no significant difference in
the mean number of days to recovery between children
with CAP who received a single high dose of vitamin D3
(100,000 IU) and those who received placebo [124, 125].
Nevertheless, the risk of a repeated CAP episode within
90 days was lower in the intervention group than in the
placebo group [124]. Choudhary et al. also concluded
that short-term oral vitamin D supplementation (1000–
2000 IU per day for 5 days) has no beneficial effect onthe resolution of severe CAP in children <5 years of age
[126]. Finally, a meta-analysis was performed to deter-
mine whether vitamin D supplementation has a useful
role in the treatment of children <5 years old with acute
CAP [127]. The authors concluded that there is no evi-
dence to support therapeutic vitamin D supplementation
in the management of children <5 years old with acute
CAP. Overall, the available data do not appear conclu-
sive on the role of vitamin D deficiency in increasing
CAP risk and do not demonstrate a beneficial effect of
vitamin D supplementation on CAP outcomes in the
acute disease phase.
Vitamin D supplementation
Available data support a role for vitamin D deficiency in
the risk of pediatric TB, rAOM and severe bronchiolitis,
whereas further studies are needed to confirm an asso-
ciation in children with recurrent pharyngotonsillitis,
ARS and CAP. Maintenance of adequate vitamin D sta-
tus could be an effective and inexpensive prophylactic
method against these RTIs, but the supplementation
regimen has not been clearly defined. In addition to the
lack of consensus on whether and in whom there is a
need of vitamin D supplementation as well as on the
ideal regimen, countries may have different recommen-
dations according to the characteristics of their popula-
tion. A clarification of the functional effect of VDRs
polymorphisms also in relation to ethnicity, sun ex-
posure, skin characteristics, and fat absorption may in-
fluence the recommended regimen. At the moment, the
supplementation schemes associated with a successful
outcome are those which evaluated cholecalciferol
1000 IU daily for 8 weeks in children treated for TB and
1000 IU daily for 4 months in those with a history of
rAOM, whereas no benefit was associated with a single
high dose of cholecalciferol (100,000 IU) or with a short-
term oral supplementation (1000–2000 UI daily for
5 days) in children with CAP. Another approach could
be the maternal vitamin D supplementation during
pregnancy in order to reduce the future RTIs risk in the
offspring, but again the ideal supplementation regimen
has not been defined. For this reason, well-defined
evidence-based guidelines on the serum 25(OH)D levels
associated with disease risk and recommended supple-
mentation regimens are urgently needed.
Conclusions
Several recent studies have shown that vitamin D has
different immunomodulatory properties associated with
the risk of RTIs in childhood. In this regard, it is very
important to understand the definition of deficiency and
insufficiency of vitamin D and when and how to treat
this condition. Unfortunately, there is no consensus,
although a level of at least 10 ng/mL 25(OH)D is
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and calcium homeostasis, and a concentration between
20 ng/mL and 50 ng/mL is considered adequate to
provide an immunomodulatory effect [128]. Overall, in
children as well as in adults, the term “vitamin D defi-
ciency” indicates values <20 ng/mL, whereas insuffi-
ciency is defined as between 20 ng/mL and 30 ng/mL,
with at least 30 ng/mL required for optimal health bene-
fits [129–131]. Although hypervitaminosis D is arbi-
trarily defined as 25(OH)D concentrations >100 ng/mL,
symptoms of vitamin D intoxication typically do not
manifest until circulating 25(OH)D concentrations rise
above 150 ng/mL [132]. With the lack of agreement on
the levels of 25(OH)D that constitute sufficiency, there
is variability in recommendations for supplementation.
Further clinical trials are needed to determine the most
appropriate vitamin D supplementation regimen, de-
pending on the type of RTI and taking into account
VDR polymorphisms.
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